Hindricks G, Potpara T, Dagres N et al (2021) 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 42:373–498. https://doi.org/10.1093/eurheartj/ehaa612

Article  PubMed  Google Scholar 

Guide parcours de soins: Fibrillation atriale Février 2014. https://www.has-sante.fr/upload/docs/application/pdf/2014-05/guide_pds_fibrillation_atriale_vf.pdf. Accessed 29 Mar 2021

Hellwig T, Gulseth M (2013) Pharmacokinetic and pharmacodynamic drug interactions with new oral anticoagulants: what do they mean for patients with atrial fibrillation? Ann Pharmacother 47:1478–1487. https://doi.org/10.1177/1060028013504741

Article  CAS  PubMed  Google Scholar 

Hanigan S, Das J, Pogue K et al (2020) The real world use of combined P-glycoprotein and moderate CYP3A4 inhibitors with rivaroxaban or apixaban increases bleeding. J Thromb Thrombolysis. https://doi.org/10.1007/s11239-020-02037-3

Article  PubMed  Google Scholar 

Zhang Y, Souverein PC, Gardarsdottir H et al (2020) Risk of major bleeding among users of direct oral anticoagulants combined with interacting drugs: A population-based nested case–control study. Br J Clin Pharmacol 86:1150–1164. https://doi.org/10.1111/bcp.14227

Article  CAS  PubMed  PubMed Central  Google Scholar 

Guideline on the investigation of drug interaction.pdf. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-drug-interactions-revision-1_en.pdf. Accessed 5 Oct 2021

Chang S-H, Chou I-J, Yeh Y-H et al (2017) Association Between Use of Non-Vitamin K Oral Anticoagulants With and Without Concurrent Medications and Risk of Major Bleeding in Nonvalvular Atrial Fibrillation. JAMA 318:1250–1259. https://doi.org/10.1001/jama.2017.13883

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mo Y, Karakas-Torgut A, Pham AQ (2020) Evaluation of Potential Drug-Drug Interactions With Direct Oral Anticoagulants in a Large Urban Hospital. J Pharm Pract 33:136–141. https://doi.org/10.1177/0897190018788264

Article  PubMed  Google Scholar 

Bezabhe WM, Bereznicki LR, Radford J et al (2020) Five-Year Trends in Potential Drug Interactions with Direct-Acting Oral Anticoagulants in Patients with Atrial Fibrillation: An Australian-Wide Study. J Clin Med 9. https://doi.org/10.3390/jcm9113568

Tuppin P, Rudant J, Constantinou P et al (2017) Value of a national administrative database to guide public decisions: From the système national d’information interrégimes de l’Assurance Maladie (SNIIRAM) to the système national des données de santé (SNDS) in France. Rev DÉpidémiologie Santé Publique 65:S149–S167. https://doi.org/10.1016/j.respe.2017.05.004

Article  Google Scholar 

Bezin J, Duong M, Lassalle R et al (2017) The national healthcare system claims databases in France, SNIIRAM and EGB: Powerful tools for pharmacoepidemiology. Pharmacoepidemiol Drug Saf 26:954–962. https://doi.org/10.1002/pds.4233

Article  PubMed  Google Scholar 

Thesaurus des interactions medicamenteuses (2020) https://ansm.sante.fr/var/ansm_site/storage/original/application/c8f2002151b0bb58d1936f9e50ed1d55.pdf. Accessed 11 Feb 2021

Hügl B, Horlitz M, Fischer K, Kreutz R (2023) Clinical significance of the rivaroxaban–dronedarone interaction: insights from physiologically based pharmacokinetic modelling. Eur Heart J Open 3:oead004. https://doi.org/10.1093/ehjopen/oead004

Cheong EJY, Goh JJN, Hong Y et al (2018) Rivaroxaban With and Without Amiodarone in Renal Impairment. J Am Coll Cardiol 71:1395–1397. https://doi.org/10.1016/j.jacc.2018.01.044

Article  PubMed  Google Scholar 

Friberg L (2018) Safety of apixaban in combination with dronedarone in patients with atrial fibrillation. Int J Cardiol 264:85–90. https://doi.org/10.1016/j.ijcard.2018.02.055

Article  PubMed  Google Scholar 

Méthodologie médicale de la cartographie des pathologies et des dépenses, version G7 (années 2012 à 2018) Mise à jour: 17 février 2020. https://www.ameli.fr/fileadmin/user_upload/documents/Methodologie_medicale_cartographie.pdf. Accessed 27 May 2021

Maura G, Blotière P-O, Bouillon K et al (2015) Comparison of the short-term risk of bleeding and arterial thromboembolic events in nonvalvular atrial fibrillation patients newly treated with dabigatran or rivaroxaban versus vitamin K antagonists: a French nationwide propensity-matched cohort study. Circulation 132:1252–1260. https://doi.org/10.1161/CIRCULATIONAHA.115.015710

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hirsh Raccah B, Rottenstreich A, Zacks N et al (2018) Drug interaction as a predictor of direct oral anticoagulant drug levels in atrial fibrillation patients. J Thromb Thrombolysis 46:521–527. https://doi.org/10.1007/s11239-018-1738-7

Article  CAS  PubMed  Google Scholar 

Frost CE, Byon W, Song Y et al (2015) Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor. Br J Clin Pharmacol 79:838–846. https://doi.org/10.1111/bcp.12541

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lee JY, Oh I-Y, Lee J-H et al (2021) Drug-drug interactions in atrial fibrillation patients receiving direct oral anticoagulants. Sci Rep 11:22403. https://doi.org/10.1038/s41598-021-01786-2

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lupercio F, Romero J, Peltzer B et al (2018) Efficacy and Safety Outcomes of Direct Oral Anticoagulants and Amiodarone in Patients with Atrial Fibrillation. Am J Med 131:573.e1-573.e8. https://doi.org/10.1016/j.amjmed.2017.11.047

Article  CAS  PubMed  Google Scholar 

Pham P, Schmidt S, Lesko L et al (2020) Association of Oral Anticoagulants and Verapamil or Diltiazem With Adverse Bleeding Events in Patients With Nonvalvular Atrial Fibrillation and Normal Kidney Function. JAMA Netw Open 3:e203593. https://doi.org/10.1001/jamanetworkopen.2020.3593

Bartlett JW, Renner E, Mouland E et al (2019) Clinical Safety Outcomes in Patients With Nonvalvular Atrial Fibrillation on Rivaroxaban and Diltiazem. Ann Pharmacother 53:21–27. https://doi.org/10.1177/1060028018795140

Article  CAS  PubMed  Google Scholar 

Proietti M, Cheli P, Basili S et al (2017) Balancing thromboembolic and bleeding risk with non-vitamin K antagonist oral anticoagulants (NOACs): A systematic review and meta-analysis on gender differences. Pharmacol Res 117:274–282. https://doi.org/10.1016/j.phrs.2017.01.004

Article  CAS  PubMed  Google Scholar 

Pancholy SB, Sharma PS, Pancholy DS et al (2014) Meta-Analysis of Gender Differences in Residual Stroke Risk and Major Bleeding in Patients With Nonvalvular Atrial Fibrillation Treated With Oral Anticoagulants. Am J Cardiol 113:485–490. https://doi.org/10.1016/j.amjcard.2013.10.035

Article  CAS  PubMed  Google Scholar 

Poli D, Antonucci E, Testa S et al (2013) Gender differences of bleeding and stroke risk in very Old atrial fibrillation patients on VKA treatment: Results of the EPICA study on the behalf of FCSA (Italian Federation of Anticoagulation Clinics). Thromb Res 131:12–16. https://doi.org/10.1016/j.thromres.2012.10.009

Article  CAS  PubMed  Google Scholar 

Washam JB, Hellkamp AS, Lokhnygina Y et al (2017) Efficacy and Safety of Rivaroxaban Versus Warfarin in Patients Taking Nondihydropyridine Calcium Channel Blockers for Atrial Fibrillation (from the ROCKET AF Trial). Am J Cardiol 120:588–594. https://doi.org/10.1016/j.amjcard.2017.05.026

Article  CAS  PubMed  Google Scholar 

La situation des EHPAD en 2017. Analyse de la gestion des établissements d’hébergement pour personnes âgées dépendantes et de la prise en charge des résidents. https://www.cnsa.fr/documentation/cnsa_portrait_ehpad_2017_vf.pdf. Accessed 21 Mar 2023

Potpara TS, Ferro CJ, Lip GYH (2018) Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction. Nat Rev Nephrol 14:337–351. https://doi.org/10.1038/nrneph.2018.19

Article  CAS  PubMed  Google Scholar 

Souty C, Launay T, Steichen O et al (2020) Use of the French healthcare insurance database to estimate the prevalence of exposure to potential drug-drug interactions. Eur J Clin Pharmacol 76:1675–1682. https://doi.org/10.1007/s00228-020-02952-7

Article  PubMed  Google Scholar 

Cunningham A, Stein CM, Chung CP et al (2011) An automated database case definition for serious bleeding related to oral anticoagulant use. Pharmacoepidemiol Drug Saf 20:560–566. https://doi.org/10.1002/pds.2109

Article  PubMed  PubMed Central  Google Scholar 

Lévesque LE, Hanley JA, Kezouh A, Suissa S (2010) Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ 340:b5087. https://doi.org/10.1136/bmj.b5087

Suissa S (2007) Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf 16:241–249. https://doi.org/10.1002/pds.1357

Article  PubMed  Google Scholar